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Abstract 
Title: Cerebral Venous Thrombosis (CVT): Long-Term Vocational Outcome Study 
Author, year: Erik Lindgren, 2016 
Institution, city, country: Department of Neurology, Sahlgrenska University Hospital, 
Gothenburg, Sweden AND Institute of Neuroscience and Physiology, Sahlgrenska Academy 
at University of Gothenburg, Gothenburg, Sweden. 
Background: Cerebral venous thrombosis (CVT) is an uncommon form of stroke mainly 
affecting working aged individuals and predominantly females. Long-term consequences and 
outcomes of CVT are not well described. 
Aim: To investigate long-term functional outcome in patients with CVT in terms of 
vocational activity. 
Methods: All CVT patients diagnosed and treated in the Sahlgrenska University Hospital 
between 1997 and 2015 were retrospectively investigated through medical records. Surviving 
patients fulfilling the study criteria were invited to a clinical long-term follow-up visit. 
Results: Of 90 survivors at working-age, 39 were followed-up (mean onset age 39 y, 62 % 
female). At the end of follow-up (median 134 months), 55 % of patients were fully recovered 
(modified Rankin scale, [mRS] =0-1), whereas 16 % reported significant disabilities (mRS=3-
5). Most frequent residual symptoms were concentration or memory disorder (62 %), severe 
headaches (39 %), psychiatric problems (35 %), and fatigue (29 %). One quarter (28 %) was 
not able to return to work; following consequences from their CVT. Age and sex adjusted 
predictors for work return were absence of acute infarction (Hazard Ratio [HR]=3.8), absence 
of acute intracranial event (HR=2.5), oral contraceptive use among females (HR=3.3), straight 
sinus thrombosis (HR=3.5) and male sex (HR=3.3). 
Conclusions: Long-term CVT residual symptoms seem to have negative impact on working 
life. Individual predictors for work return were absence of acute infarction, absence of acute 
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intracranial event, oral contraceptive use among females, straight sinus thrombosis and male 
sex.  
Key Words: Intracranial Thrombosis, Outcome, Prognosis.  
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Background 
Anatomy 
Venous capillaries draining the brain assemble 
in venules inside the parenchyma. Cortical 
veins upon the cerebellar convexity, empties in 
bridging veins and pass through the 
subarachnoid room on their way to the sinus 
durae matris, consisting of one periosteal and 
one dural layer. The superior sagittal sinus and 
the inferior sagittal sinus drain the superficial 
and the deep venous system, respectively (Fig. I). Deep cerebral veins drain anteriorly to the 
cavernous sinus, or posteriorly via vein of Galen, joins with the inferior sagittal sinus into the 
straight sinus, which further drains into confluence of sinuses. Transverse sinuses are formed 
bilaterally, following posterior cranial fossa, forming sigmoid sinuses on each side, leaving 
the intracranial space as the internal jugular veins. The cavernous sinus is a venous plexus 
located superiorly to Sella Turcica, with a close connection to important anatomical structures 
such as the internal carotid, oculomotor-, trochlear-, ophthalmic-, and the abducens nerve. 
Vein of Trolard (superior anastomotic vein) between superior sagittal sinus and the superficial 
medial cerebral vein in the Sylvian fissure, and vein of Labbé (inferior anastomotic vein) 
between the superficial medial cerebral vein and the sigmoid sinus, facilitate alternative paths 
in case of vein occlusion (1). 
Pathogenesis 
Symptoms and signs of sinus thrombosis can be divided into two main groups depending on 
whether the cause is thrombosis in cerebral veins - causing local effects, or thrombosis in 
Figure I. Anatomy of cerebral dural sinuses 
and veins (63). 
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major sinuses - causing intracranial hypertension (Fig. II). Frequently, both mechanisms occur 
simultaneously.  
 
Occlusion of cerebral veins leads 
to obstruction of venous blood 
flow and can cause hyperemia, 
localized edema or even brain 
infarction. Depending on 
individual anatomy and location 
of the occlusion, collateral veins 
may decrease the amount of damage caused. Cytotoxic edema is caused by ischemia, leading 
to intracellular swelling. Vasogenic edema is formed by eruption of the blood-brain barrier, 
leading to leakage of blood plasma and may cause brain tissue damage. The latter is reversible 
by treating underlying condition (2-4). Normally, cerebrospinal fluid is transported from the 
subarachnoid space through arachnoid villi into the superior sagittal sinus. Thrombus formed 
in the large venous channels may obstruct the venous outflow and block transport of 
cerebrospinal fluid from the subarachnoid space to the blood, and thereby cause increased 
intracerebral pressure (2, 3).  
Historical Perspective 
Cerebral venous thrombosis (CVT) was first recognized in 1825, by a French physician, Dr. 
M.F Ribes, describing a patient presenting with severe headache and seizure, as a cause of 
thrombosed superior sagittal and lateral sinuses (5). A few years later, the English physician 
John Abercrombie published a case report on a 24-year old woman developing headaches and 
seizures during her puerperium. Later, she died from status epilepticus. Autopsy revealed a 
thrombosis of the superior sagittal sinus and cortical veins (6). Confirmation of diagnosis has 
Figure II. Enhanced computerized tomography on thrombosed 
superior sagittal sinus: A) Axial view, B) Sagittal view (64). 
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changed over time and currently relies on radiological imaging of the dural sinuses and 
cerebral veins (7). The largest prospective study on CVT so far is the International Study on 
Cerebral Venous and Dural Thrombosis (ISCVT). From May 1998 to May 2001, 624 patients 
were included with a median follow-up of 16 months. Primary outcomes were death and 
dependency assessed by the modified Rankin Scale (8). 
Epidemiology 
Cerebral venous thrombosis is a fairly uncommon disease, believed to account for 0.5-1 % of 
all strokes, but the correct incidence is uncertain (2, 9). Early studies based on autopsy series 
suggest an incidence of 0.1-0.2/100.000 years, based on a prevalence of CVT of 9.3 % among 
182 consecutive patients (10, 11). In a nation-wide study from Portugal based on 
investigations from late 1990:s, the incidence was 0.22/100.000/year (12). A cross-sectional 
study from the Netherlands reported an incidence of 1.32/100.000/year (13). However, 
improvements in radiological techniques allow less severe cases to be detected and may not 
only explain the increase in incidence, but also main part of the steady decrease in case 
fatality. A meta-analysis showed decreased case fatality from studies published prior to the 
millennium shift, whereafter the curve stabilized around 5-10 % (14). The case fatality is 
relatively lower than in other strokes, but the CVT patients are significantly younger. In the 
ISCVT, 78 % of CVT cases occurred in patients <50 years of age (8), compared to stroke in 
general where merely 31 % of the cases occur in patients younger than 65 years (15). Mean 
age among adults is 39 years (12). What furthermore differs from arterial stroke is the 
distribution between sexes. CVT is significantly more prevalent among women than men 
(16).  
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Risk Factors and Etiology 
Predisposing causes to CVT are multiple and often combined (17). In the ISCVT cohort, 43.6 
% had more than one known risk factor (Table I) (8). Virchow’s triad (Fig. III) with decreased 
blood flow, vessel damage or disease, and relative hypercoagulation, are all important 
considerations in etiologic studies. Risk factors are usually divided into two major groups: 
acquired- and genetic risks. Coagulopathies with increased risk of extracerebral venous 
thrombosis have been reported to increase risk for CVT as well (18).  
Prothrombotic Conditions 
Risk factors frequently associated with CVT 
are miscellaneous prothrombotic conditions. 
In the ISCVT cohort with 624 patients, 34 
% had inherited or acquired prothrombotic 
conditions (8), slightly higher occurrence 
than in an American study, reporting 21 % 
among 182 CVT case subjects (19).  
Genetic Thrombophilia 
A number of genetic factors predisposing for venous thrombosis have been found to be 
associated with CVT in small patient series; however, a full picture of the genetic 
backgrounds of the disease has not yet been explored. Affected individuals are particularly 
young, and therefore have low exposure to environmental factors, predicting a good chance of 
finding genetic markers associated to CVT. 
Anticoagulation Protein Deficiencies 
Antithrombin III-, protein C- and protein S deficiency, have been associated with CVT. Two 
comparable case-control studies with in total 172 CVT patients and 362 healthy control 
subjects, showed a combined odds ratio (OR) of 11.1 for protein C deficiency (95 % 
Figure III. Virchow’s triad - risk factors for venous 
thrombosis (65). 
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confidence interval [CI] 1.87 to 66.05), and 
12.5 for protein S deficiency (95% CI 1.45 to 
107.29) (18, 20, 21). 
Factor V Leiden Gene Mutation 
The prothrombotic Factor V plays an important 
role in coagulation. Normally, the 
anticoagulant active Protein C (APC) inhibits 
and decomposes Factor Va. A certain mutation 
in Factor V, also internationally known as 
factor V Leiden mutation, modifies the binding 
site, causing a resistance to activated protein C 
and thereby a decrease of decomposition of 
Factor Va (22). A meta-analysis of 13 studies, 
including 469 CVT cases and 3023 control 
subjects, reported an association between 
Factor V Leiden mutation and CVT, 
(OR=3.38, 95 % CI 2.27 to 5.05) (18, 23). In 
Scandinavian countries, the prevalence of 
Factor V Leiden among general populations is 
10-15 %. Factor V Leiden mutation is the most 
common genetic risk factor for thrombosis in 
general (22).  
Prothrombin G20210A Mutation 
A Guanine →Adenine transition in the 
prothrombin gene, slightly increase level of prothrombin, and is associated with CVT. The 
Table I. Causes and Risk Factors 
Associated with Cerebral Venous Sinus 
Thrombosis (2). 
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prevalence is 2 % in a white population (24). A meta-analysis reported pooled OR of CVT of 
9.27 (95 % CI 5.85 to 14.67) (23, 25). 
Acquired Thrombophilia 
Antiphospholipid and Anticardiolipin Antibodies, Hyperhomocysteinemia 
Elevated levels of antiphospholipid and anticardiolipin antibodies have been associated with 
CVT in various studies, including ISCVT study where 5.9 % of the patients had increased 
levels (8). Hyperhomocysteinemia is a known risk factor for DVT, although not yet shown to 
increase risk of CVT.  
Gender-Specific Risk Factors 
In young women, particularly important from a CVT point of view, the most frequent risk 
factors are oral contraceptive use, pregnancy, and puerperium, all causing elevated levels of 
estrogen (8). Additional associated gender-specific risk factors are hormone replacement 
therapy, the day-after pill, and in vitro fertilization (26). As mentioned before, CVT is 
significantly more common among women than men. On the other hand, women with gender-
specific risk factors have better prognosis – complete recovery (modified Rankin Scale [mRS] 
=0-1) 85 % after 6 months versus 71 % among men (8, 16).  
Cancer  
Hematological and solid malignancies seem to be associated with CVT. Preliminary data from 
an unpublished multicenter study predict increased risk of CVT in patients with cancer, 
compared to those without (OR=4.4, 95 % CI 3.2 to 6.2) (27). Theoretically, CVT can be 
caused by cancer in at least 3 different ways: 1) direct effect of the tumor – local meningioma 
or metastases could increase pressure, or grow into the sinuses, 2) coagulation disturbance, 
and 3) cancer treatment. In particular L-Asparaginase and intrathecal chemotherapy are highly 
suspected to be associated with CVT (22). 
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Infections 
Infectious causes of CVT have declined in developed countries as antibiotic treatment 
improved. However, nervous system infections are likely to remain an important cause in 
developing countries. Nowadays local infections in the cranial area such as otitis, mastoiditis, 
and sinusitis, account for the majority of infectious etiology, generally causing the rare 
cavernous sinus thrombosis (28).  
Other Causes 
Other potential causes and conditions associated with CVT mainly in small case reports, are 
hematological diseases – polycythemia, thrombocythemia and anemia (7), inflammatory 
bowel disease, nephrotic syndrome and dehydration (8). Dural sinuses and veins are 
vulnerable and at risk during neurosurgical procedures and interventions. Cranial traumas 
could also cause damage to the cerebral venous sinuses. Intracranial hypotension could cause 
increased tension in meninges and thereby increase risk of clotting. Reports suggesting 
lumbar puncture as a risk factor, often consider intracranial hypotension as the cause (18). In 
the ISCVT population, no underlying risk factor was found in 12.5 % of the patients (8). 
Clinical Manifestations and Diagnosis 
Symptoms 
CVT presents with a wide panorama of symptoms, ranging from isolated headache to coma. 
Most patients present with severe headache although other common baseline symptoms 
include nausea, seizures, severe focal neurological deficits, and altered consciousness. 
Furthermore, clinical onset differs from acute to subacute or even chronic. In the ISCVT 
patients, 37 % of onsets were acute (<48 hours), 56 % subacute (>48 hours to 30 days), and 7 
% chronic (>30 days). Median delay from onset of symptoms to hospital admission was four 
days and onset to diagnosis seven days (8). 
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Clinical picture partly depends on the location and extent of thrombosis (Table II), age of the 
patient, presence of parenchymal lesions, and time to diagnosis. By grouping symptoms and 
signs, three syndromes are frequently identified and related to a specific medical condition: 1) 
isolated intracranial hypertension – headache, visual acuity defect, diplopia, and papilledema, 
2) focal symptoms – neurological deficits or seizures, and 3) subacute diffuse encephalopathy 
– bilateral- or multifocal signs, delirium or dysexecutive disturbances. Less frequent 
syndromes include cavernous sinus syndrome, subarachnoid hemorrhage generalized or 
localized to cortical sulci, and syndromes of the lower cranial nerves, including multiple 
palsies (7).  
A generalized headache is the most frequent symptom (Table III), often described as diffuse 
and progressive over days to weeks. A minority of patients present with thunderclap 
headache, resembling of subarachnoid hemorrhage. Headache was present in 90 % of adult 
patients in the ISCVT (8). Isolated headache without focal neurological symptoms or 
papilledema occurs in up to 25 % of patients with CVT. Another 25 % presents with headache 
in combination with papilledema or sixth nerve palsy (29). However, headache is a clearly 
non-specific symptom, and the vast majority of patients with isolated headache do not have 
CVT. Absence of headache is more common among relatively elderly patients, patients with 
malignancy, isolated cortical vein thrombosis, and among men (30). 
Location of Thrombosis Characteristic Symptoms 
Superior Sagittal Sinus Headache, symptoms of increased intracranial pressure, papilledema 
Lateral sinus thrombosis Symptoms from middle ear infection, fever, ear discharge, pain in ear 
mastoid, increased intracranial pressure 
Cortical involvement Hemianopia, contralateral weakness, aphasia 
Deep venous system Thalamic or basal ganglia symptoms – rapid neurological deterioration, 
paraparesis, alteration in consciousness in the absence of focal findings. 
Bilateral brain involvement is not infrequent. 
Table II. Localization of cerebral venous thrombosis and its relationship with clinical symptoms (18). 
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Thirty to forty percent of patients present with 
intracranial hemorrhage (ICH). Parenchymal lesions 
and focal brain injuries often present with seizures or 
focal neurological deficits, mostly hemiparesis and 
aphasia (8, 31, 32). Forty percent of patients present 
with any type of motor or sensory deficits (8). 
Approximately 40 % of patients suffer from one or 
more seizures in the acute phase, either focal or 
generalized (8, 18). 
Diagnosis 
D-dimer 
Elevated D-dimer is associated with CVT, especially 
together with acute onset of symptoms and greater 
thrombus extension. However, there are many causes 
of elevated d-dimer, thus the role of D-dimer in 
diagnosis of CVT is limited. Low levels of D-dimer 
cannot exclude CVT suspicions, nevertheless, high 
levels can help identify patients with low probability of CVT (33). 
Radiology and Location 
Diagnosis of CVT requires visualization of the thrombus, in combination with insufficient 
flow in the dural sinuses or cerebral veins. Direct signs include cord sign, delta sign and with 
contrast the empty delta sign of dural sinuses (Fig. IV). The most common indirect signs are 
ICH and localized cerebral edema. Venous hemorrhagic infarction and juxtacortical 
hemorrhage are both associated with CVT. The latter is strictly associated with thrombus in 
Table III. Presenting symptoms and sinuses 
thrombosed in cerebral venous thrombosis (8). 
Symptoms and signs %
Headache 88.8
Visual Loss 13.2
Papilledema 28.3
Diplopia 13.5
Stupor or Coma 13.9
Aphasia 19.1
Mental Status Disorders 22.0
Left paresis 20.4
Right paresis 20.4
Any paresis 37.2
Bilateral motor signs 3.5
Focal seizure 19.6
Seizure with generalization 30.0
Any seizure 39.3
Sensory symptoms 5.4
Other focal cortical sign 3.4
Thrombosed sinus %
Superior sagittal sinus 62.0
Lateral sinus, left 44.7
Lateral sinus, right 41.2
Straight sinus 18.0
Deep venous system 10.9
Cortical veins 17.1
Jugular veins 11.9
Cerebellar veins 0.3
Cavernous sinus 1.3
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the superior sagittal sinus (32). In case of ICH of unclear origin, or cerebral infarction over 
typical arterial areas – imaging of the venous system is recommended (18). 
 
There are essentially three imaging techniques to diagnose CVT: Magnetic Resonance 
Imaging (MRI) with MR-venography (MRV), computed tomography (CT) with CT-
venography, and catheter angiography (18). Most sensitive is the MRI in combination with 
MRV. Frequently used are time-of flight sequences measuring venous flow, and contrast 
enhanced MRV. Absence of flow void (no-flow phenomenon) in combination with variation 
in signal within the sinus or vessel, are major early signs for CVT. Imaging signal may differ 
depending on the age of the thrombus. Disadvantages are lack of availability, risk of motion 
artifacts, and long examination time (3).  
 
Unenhanced CT often displays pictures without findings indicative of CVT and merely 
detects approximately 30 % of cases. Such findings could be hyperdensity of a dural sinus or 
cortical vein, in posterior part of superior sagittal sinus appearing as a delta- or filled delta 
Figure IV. Computed tomography findings on sinus thrombosis A) Venous infarction with 
midline shift as a cause of major superior sagittal sinus thrombosis. B) Dense clot sign, 
here indicative of superior sagittal sinus thrombosis. C) Dense clot sign in transverse 
sinuses bilaterally. D) Empty delta sign where contrast leaves out an empty ring at site of 
thrombus (64). 
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sign. Anatomic variations of the dural sinuses further complicate the diagnosis, resulting in 
insufficient sensitivity for CT in absence of contrast. However, plain CT has its place in 
excluding tumor, subdural hematoma, or abscess (9, 34). 
 
CT-venography with contrast is a faster and less expensive alternative to MRV, yet more 
sensitive than unenhanced CT. Bone artifacts from the cortical bone may interfere with 
imaging of the sinus. Diagnostic difficulties may occur in confirming the thrombus during the 
first days after onset. However, as a result of the complicated presentation, patients often 
present in a subacute or chronic manner, making CT-venography an important diagnostic tool. 
Overall accuracy of combined CT and CT-venography is 90-100 %, and considered equal to 
MRV in diagnostic power of CVT (18).  
 
As radiological imaging techniques improve, CVT diagnosis become less dependent on 
invasive methods. In cases with still uncertain diagnosis after CT-venography or MRI, 
cerebral angiography may be indicated. Cortical veins and variations in deep venous 
structures may be hard to visualize with CTV and MRV. In these cases, cerebral 
angiographies still play an important role, despite being more invasive. Positive findings 
include insufficient, delayed or failure of cerebral sinus and vein appearance. Cerebral 
angiography is a prerequisite for endovascular procedures (18). 
Treatment 
Independently of type of stroke, organized stroke care has shown great beneficial effects in 
the acute care. Studies stating, inter alia, 14 % reduction in odds of death at one year 
(OR=0.86, 95 % CI 0.76 to 0.98), death or institutionalization (OR=0.82, 95 % CI 0.73 to 
0.92) and death or dependency (OR=0.82, 95 % CI 0.73 to 0.92) (35, 36).  
 
Cerebral Venous Thrombosis (CVT): Long-Term Vocational Outcome Study  
 
 
 
2016-05-30  17 
Primary treatment with low molecular heparin has limited evidence from randomized clinical 
trials; however, hemorrhagic complications during anticoagulation with heparins are low or 
even non-existing (37-39). Immediate heparin treatment is recommended by international 
guidelines (18, 40). Low molecular-weight heparin has better safety profile and is generally 
preferred over unfractioned heparin, except in cases at risk for neurosurgical intervention 
where rapid reversal of anticoagulation may be necessary (3, 41, 42). 
 
For cases deteriorating despite proper anticoagulant treatment, local thrombolysis and 
mechanical extraction of thrombotic material may be considered. These recommendations are 
based upon small case series and case reports, thus not suggested as standard treatment (18). 
Despite absence of randomized trials, decompressive hemicraniectomy has its place in 
patients at risk of transtentorial herniation, the most frequent cause of death in the acute stage 
of CVT. Management of intracranial pressure is vital in prevention of fatal consequences (43, 
44). 
 
A clinical presentation without seizures means low risk of seizures occurring during the 
course. In contrast, patients presenting with seizures have a high risk of recurrence, indicating 
use of preventive anticonvulsive drugs (45, 46). 
 
Recurrence of extracranial thrombosis occurs in 4 % of patients and recurrence of CVT in 2 
% of patients during the first year after diagnosis (8). In patients with transient risk factors, 
recommended treatment duration with vitamin K antagonists is 3 to 6 months. In patients with 
unprovoked CVT, recommended duration is 6 to12 months. Permanent anticoagulation is 
recommended in patients with severe thrombophilia or recurrent CVT. However, the optimal 
duration of treatment remains uncertain (18). Further use of contraceptives or other estrogen 
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is contraindicated. During pregnancies, subcutaneous treatment with low molecule weight 
heparin is indicated. 
Outcome  
Stroke outcome is often measured through the modified Rankin Scale (mRS) ranging from a 
score of 0 representing no symptoms at all, to the score of 6, representing death. A score >2 
indicates functional dependence (App. I). Overall vital and functional prognosis in CVT is far 
better than arterial stroke. Short term functional outcome is considered good with 79 % of the 
patients achieving functional independency. Another 10 to 15 % of the patients remains 
dependent and requires help in their daily routine activities. In the ISCVT, 3.4 % died within 
30 days (8, 47). However, higher case-fatality have been reported from Pakistan (6 %) (28), 
United States (13 %) (48) and Iran (15 %) (49). Few prospective studies have been performed 
describing long-term outcome, all measured with the mRS (8, 50, 51). In the ISCVT, risk 
factors for poor long-term prognosis were malignancy, thrombosis of the deep venous system, 
intracranial hemorrhage on admission, Glasgow Coma Scale <9, mental status disturbance, 
age >37, male sex and central nervous system infection (8). A recent study additionally 
suggests high admission glycaemia being a predictor for poor clinical outcome (52). A 
retrospective study conducted in Helsinki, Finland by Hiltunen et al. (n=161, median follow 
up time 39 months) reports good clinical long-term outcome with 81 % scoring 0-1 on the 
mRS. In contrast, only 57 % had returned to work at end of follow up (53). Mental 
depression, anxiety, cognitive deficits and/or concentration impairments are present in 
approximately half of CVT patients and appear to have negative impact on psychosocial and 
employment status (53-55). Long-term functional outcome after CVT may be considered 
good when measured with mRS, however, long-term functional outcome regarding working 
ability, cognitive dysfunction, headache, and depression rate after CVT, remains poorly 
investigated.  
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Aims 
Primary aim of this study was to investigate long-term functional outcome in terms of return 
to work, dependency in activities of daily living, and residual symptoms in patients with CVT. 
 
Secondary aim was to investigate etiological-, clinical-, radiological-, laboratorial- and 
genetic characteristics of adult patients with diagnosis of CVT, admitted to the Sahlgrenska 
University Hospital, Gothenburg, with onset between 1997-01-01 and 2015-01-01.  
Methods 
All patients between 1997 and 2015 with a verified diagnose of CVT, admitted to the 
Sahlgrenska University Hospital, were searched for in the Sahlgrenska University Hospital 
Patient Administrative Databank, using the codes of diagnosis for CVT; ICD-9: 1.4376A 
(Nonpyogenic thrombosis of intracranial venous sinus), ICD-10: I63.6 (Cerebral infarction 
due to cerebral venous thrombosis, nonpyogenic), I67.6 (Nonpyogenic thrombosis of 
intracranial venous system), O87.3 (Cerebral venous thrombosis during puerperium) and 
O.22.5 (Cerebral venous thrombosis during pregnancy). It was predicted to find 
approximately 10 patients each year. Therefore, the aim was to include 150 patients, 
considering that some patients could not be reached, and some would not wish to participate. 
Patients with onset earlier than 1997-01-01 or later than 2015-01-01 were excluded together 
with cases in whom the diagnosis could not be verified according to medical journal, patients 
with onset age younger than 18 years as well as duplicate registrations.  
Part 1 – Baseline 
Remaining patients were considered eligible to the first part of the study where baseline 
characteristics were investigated. Medical records were reviewed to gather demographics, risk 
factors, clinical features, radiological imaging, laboratory findings, complications, and similar 
relevant information. The data were entered to a SPSS-based database. Altogether, 150 
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variables were registered on each patient. Baseline information included: gender, medication, 
educational level, employment status, previous and current diseases, in particular previous 
thrombosis, malignancy, polycythemia vera, essential thrombocythemia, vasculitis, 
inflammatory bowel disease, chronic headaches, body weight, height, body mass index, 
known allergies, smoking, alcohol use, previous pregnancy, exposure of pregnancy, 
puerperium, systemic infection, local infection, mechanical trauma or surgery, oral 
contraceptive use, lumbar puncture, and hormone replacement therapy within the last 3 
months preceding CVT onset. Family history of: CVT, other venous thrombotic disease, 
stroke and type of stroke. Presented symptoms of CVT were: headache - type, onset 
characteristics, progression, severity and location, nausea and vomiting. Seizure – focal, 
generalized or secondary generalized, seizure in acute phase. Neurological focal deficits - 
aphasia, paresis, mental state disturbance, observed papilledema and stiff neck. Onset clinical 
condition was also measured with Glasgow Coma Scale (GCS), National Institutes of Health 
Stroke Scale (NIHSS) and the mRS, constructed retrospectively (56, 57).  
 
Radiological findings were gathered from radiological records, CT, CTV, MRI, MRV, and 
cerebral angiography, during the hospital stay. Some records were reviews on images from 
other hospitals concerning the current disease. In uncertain cases, the overall senior 
physicians’ clinical and radiological assessments were considered liable. Data included 
confirmed thrombus in: transverse and sigmoid sinus bilaterally, jugular internal vein 
bilaterally, superior and inferior sagittal sinuses, straight sinus, confluence sinus, cavernous 
sinus, deep venous system, cortical and cerebellar veins. Total number of sinuses thrombosed 
was calculated and recorded. Presence of parenchymal lesions – hemorrhagic or non-
hemorrhagic, infarctions, dural arteriovenous fistulas and subarachnoid hemorrhage were 
recorded. Laboratory records were reviewed in search for both acquired - Lupus 
Cerebral Venous Thrombosis (CVT): Long-Term Vocational Outcome Study  
 
 
 
2016-05-30  21 
Anticoagulant (Dilute Russell Viper Venom Test, DRVV) and antiphospholipid antibodies, 
and genetic thrombophilia - factor V Leiden mutation, prothrombin G20210 A mutation, 
protein C deficiency, protein S deficiency, and antithrombin III deficiency. In hospital 
treatment was recorded as intravenous or subcutaneous anticoagulation, oral anticoagulation, 
antiepileptic drugs, local thrombolysis, decompressive craniectomy, hematoma evacuation, 
and other surgical procedure. Complications were defined as any event recorded as treatment 
complication in the medical journal or previously not confirmed bleeding. Outcome at 
discharge was recorded according to the mRS, NIHSS and GCS.  
Part 2 – Long-Term Follow-Up 
Patients aged over 63 years at onset were not included in the analysis of vocational outcome. 
Medical records in general do not contain specific data on employment and deceased patients 
were therefore also excluded. Patients living abroad were also excluded as they were expected 
to be difficult to reach. Remaining patients were sent a letter containing comprehensible 
information about the study and invitation to participation (App. II). Patients were given an 
opportunity to achieve additional information by phone and asked to return a written consent 
(App. III). Patients were informed about the possibility of breaking the agreement at any time 
during the study. Those who did not return the response letter were contacted by telephone to 
investigate whether the patients were willing to participate or not. Individuals not able to 
reach were excluded. After receiving confirmation of participation in the long-term functional 
outcome and/or genetic study, a postal questionnaire was sent including study-specific 
questions regarding headache, living- and working situation and a battery of validated 
instruments measuring outcome after stroke (Stroke Impact Scale [SIS]), depression (Hospital 
Anxiety and Depression Scale [HAD]), fatigue (the Daily Fatigue Impact Scale [D-FIS]), 
health-related quality of life (EQ-5D) and life satisfaction (Lisat-11) (App. IV). Patients also 
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received an invitation to a clinical visit. In this report, results from questions regarding 
working situation is presented.   
 
Patients, who were not able to take part in a clinical visit, were asked to return their forms by 
mail. As an alternative to the clinical visit, they were offered to be contacted by telephone. 
Patients who returned their questionnaires but did not participate in follow-up, were not 
included in the analysis of this report. Some patients were able to reach, but did not decide 
Figure V. Flow chart on number of patients participating in Cerebral Venous Thrombosis (CVT): 
Long-Term Vocational Outcome Study. 
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whether they wanted to participate or not, and were also excluded. Reasons for not taking part 
in the clinical visit were living too far away or not being able to take time off from work. At 
follow-up, patients were given the opportunity to achieve additional information about the 
study face to face. Oral consent was documented in the medical record.  
 
Clinical visits were conducted from 2016-03-11 to 2016-04-29 at the Sahlgrenska University 
Hospital including a detailed interview and neurological examination. The interview focused 
on the patient’s current health condition, medication, complications post CVT (bleeding, 
recurrent venous thrombosis, hospitalization, miscarriage) and residual symptoms (headache, 
seizures, fatigue, concentration or memory disorder, visual problems, motor or sensory 
problems, speech disorders, spasticity, tremor, and dizziness) and CVT etiology 
(hematological/thrombotic disease, hormone-related, septic, mechanical/traumatic, 
malignancy, inflammatory disease, or cryptogenic. The interviews and examinations were 
conducted by the same physician, and standardized by a clinical questionnaire (App. I, V). 
The mRS, NIHSS, and Barthel Index (BI) scale were assessed. When applicable, missing 
baseline data was completed or clarified. Blood samples (10 ml) were collected by a licensed 
nurse, to be stored encrypted in a deep freezer at Sahlgrenska University Biobank, 
Gothenburg, for future genetic analyses.  
 
Primary outcome measures were functional outcome. Work return within time to long-term 
follow-up, mRS score 0-1, NIHSS score 0-2 and BI score 100 were considered favorable 
outcome. Work return was defined as ≥50 % gainful work (100 %=40 hours/week) or 
equivalent activity such as studying.  
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Statistical Analyses 
All statistical calculations were performed using IBM SPSS Statistics version 21. Collected 
data were compared and analyzed using quantitative descriptive statistic methods. Time to 
work return was calculated using Kaplan Meier. Cox regression analyses served to investigate 
independent factors associated with return to work within the follow-up period. Demographic 
factors, clinical findings, and radiological findings were considered possible explanations for 
patient outcome. Hazard ratio with 95 % CI was calculated individually on each variable. All 
p-values <0.10 in the univariable analysis were considered valuable to further analyses in the 
multivariable model. After adjusting for age and sex, a two-sided p-value <0.05 was 
considered significant. Based on clinical and theoretical experience, four variables were 
chosen to be put in an additional multivariable model; age >39 (median age in follow-up 
cohort), more than 2 risk factors, parenchymal- or subarachnoid hemorrhage and previous 
thrombosis. Chi square tests served to investigate association between residual symptoms at 
long-term follow-up and work return within the follow-up period. 
Ethics 
This study has been approved by the Regional Ethical Review Board in Gothenburg (2015-
01-11, Dnr: 898-15) and was carried out in accordance with the Helsinki Declaration 1964. 
The study implied no physical risk for patients included. All data was processed encrypted to 
minimize the risk of privacy violation. Patients were given the possibility to discuss their 
disease with professional personnel, but the study meant no further medical benefits. A 
prerequisite for decent mortality and outcome analysis, were the inclusion of deceased 
individuals to baseline data collection. This data was necessary to avoid bias and skewed 
patient selection. Being considerate, we did not contact relatives of the deceased patients and 
collected data from their medical records only. In addition to the patients suffering a CVT, 
relatives are also affected. Increased knowledge about etiology, predictors and outcome, could 
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increase life quality not only for the patients but also for their relatives. The potential winning 
from this project can thus be considerable from a patient and family perspective. All 
participants’ autonomy was respected and patients were informed about the possibility of 
withdrawing their consent at any time during the study. Personal data and blood samples 
would then have been erased and destroyed. 
Results 
Part 1 - Baseline Characteristics 
One hundred twenty-seven patients fulfilled the criteria for participation in part 1 of the study. 
Gender distribution was 82 females (64.6 %) and 45 males (35.4 %). Mean age at onset of 
symptoms was 43.3 years (range 18 to 80, SD=16.3), women were slightly younger than men 
42.1 years (range 18 to 69, SD=16.6) and 45.5 years (range 18 to 80, SD=15.7) respectively. 
Median onset to diagnosis was 6 days (Inter Quartile Range [IQR] 2 to 12). According to 
medical records, about one third of the patients were unemployed at onset (n=36, 30.2 %), 
among these, 14 (11.8 %) were retired due to old age, nine (7.6 %) on full-time sickness 
benefits, seven (5.8 %) on sick leave, three (2.5 %) on parental leave and three (2.5 %) job-
seekers. Eighty-three patients (69.7 %) were considered employed, categorized as workers 
(n=70, 58.8 %) or students (n=13, 10.2 %). Further demographic, clinical and radiological 
features are described in Table IV. 
Symptoms 
Most frequent presenting symptom was headache (80.2 %), followed by nausea, any focal 
neurological deficits and vomiting. Clinical presentations were diverse, and multiple 
symptoms were not infrequent. Other important symptoms were any type of seizure, visual 
defect, decreased alertness as in GCS score 9-14 and mental state disturbance. Eight patients 
presented with coma. 
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Radiological Findings 
Median number of sinuses thrombosed was 3.0 (IQR 2 to 4). The three most frequently 
occluded sinuses or veins were superior sagittal sinus, left lateral sinus and right lateral sinus. 
Upon first radiological examination, half or the patients had any parenchymal lesion (n=65, 
52.8 %). The occurrences of hemorrhagic and non-hemorrhagic lesions were similar. During 
the acute hospital stay, infarction was confirmed in 52 patients (40.9 %). 57 patients (44.9 %) 
had any parenchymal hemorrhage and 21 patients (16.9 %) had subarachnoid hemorrhage. 
Among six patients (4.7 %), a dural arteriovenous fistula (DAF) was discovered. 
Risk Factors and Etiology 
Observed risk factors are summarized in Table IV. Genetic thrombophilia and systemic 
infection were the most common risk factors in the whole group, both present in 21 cases 
(16.5 %). Other critical risk factors were infection of the head area or CNS, found in 16 
patients (12.6 %), malignancies or intracranial tumor 14 (11 %), hematological condition 
defined as polycythemia vera, essential thrombocythemia, or confirmed anemia 14 (11 %). 
Twelve patients (9.4 %) had a previous venous thrombotic event. Among women younger 
than 50 years, a majority used oral contraceptives (n=27, 51.9 %), 5 (9.4 %) were pregnant at 
onset and 6 (11.3 %) had given birth within 0-3 months prior to onset. 
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 No. of 
cases 
% Missing 
data 
Gender Specific risk n=82    
Previous pregnancy* 46 61.3 7 
Hormone Replacement 
Therapy* 
3 3.7 1 
Pregnancy 0-3 months ** 11 20.8  
Puerperium 0-3 months ** 6 11.3  
Oral contraceptives** 27 51.9 1 
Occluded sinus/vein    
Superior sagittal sinus  63 50.0 1 
Lateral sinus, left 60 47.6 1 
Lateral sinus, right 59 46.8 1 
Straight sinus 28 22.2 1 
Cortical veins 13 10.4 1 
Deep venous system 5 4 1 
Jugular veins 37 29.4 1 
Cavernous sinus 4 3.2 1 
Radiology Upon 
admission 
   
Any parenchymal lesion 65 52.8 4 
   Hemorrhagic 44 35.8 4 
   Non hemorrhagic 45 36.6 4 
Radiology during 
hospital stay 
   
Brain infarction 52 40.9  
Parenchymal hemorrhage 57 44.9  
Subarachnoid 
hemorrhage 
21 16.9 3 
Dural Arteriovenous 
Fistula 
6 4.7  
Education onset   22 
   Lacking 1 1  
   Primary 5 4.8  
   Secondary 62 59  
   Tertiary 37 35.2  
Employment onset   8 
   Employed 83 69.7  
      Worker 70 58.8  
      Student 13 10.2  
   Unemployed 36 30.2  
      Retired old age 14 11.8  
      Sickness benefits 9 7.6  
      Sick leave 7 5.8  
      Parental leave 3 2.5  
      Job-seeker 3 2.5  
 No. of 
cases 
% Missing 
data 
Female 82 64.6  
Mean onset age  43.3 y (16.3) 
   Female 42.1 y (16.6) 
   Male 45.5 y (15.7) 
Presenting symptoms    
Headache 101 80.2 1 
Any seizure 35 27.8 1 
   Generalized 32 25.4 1 
Focal symptoms 60 47.2  
Aphasia 19 15  
Paresis 43 33.9  
Mental State Disturbance 25 19.7  
Visual defect 31 24.4  
Papilledema detected 14 11  
Nausea 65 51.2  
Vomiting 54 42.5  
Decreased alertness (GCS 
9-14)  
30 23.6  
Coma (GCS <9) 8 6.3  
Neck Stiffness 3 2.4  
Risk factors and etiology    
Previous thrombosis 12 9.4  
Infection, systemic 21 16.5  
Infection, local 16 12.6  
Genetic thrombophilia 21 16.5  
Cranial trauma 3 2.4 1 
Surgery 11 8.7  
Lumbar puncture 2 1.6 1 
Dehydration 9 7.1  
Malignancy/intracranial 
tumor 
14 11  
Chronic headache disease 12 9.4  
Smoking 13 16.7 49 
Hematological condition 14 11  
   Severe Anemia 10 7.9  
   Essential 
   Thrombocythemia 
3 2.4  
   Polycythemia Vera 1 0.8 2 
Vasculitis 0 0  
Inflammatory Bowel 
Disease 
6 4.7  
Family history CVT 0 0 68 
Family history  
thrombosis 
19 33.3 70 
Table IV. Baseline data on 127 patients with Cerebral Venous Thrombosis (CVT). 
Data appear as n (%) or mean (Standard Deviation) 
*Among females n=82 
** Among females <50 y, n=53 
Y – years, GCS-Glasgow Coma Scale, CVT – Cerebral Venous Thrombosis 
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Treatment and Outcome at Discharge 
Almost all patients received intravenous (IV) 
or subcutaneous (SC) anticoagulation 
treatment (n=118 patients, 93.7 %). Local 
thrombolysis was performed in 24 patients 
(18.9 %) out of which 10 (41.7 %) had no 
complication to the treatment. Bleeding 
occurred in six patients (25 %) and other 
complications as clinical worsening or new 
neurological symptoms in eight patients (33.3 
%). In the group without local thrombolysis 
(n=103), 92 patients (89.3 %) had no 
complication. Bleeding occurred in six (5.8 
%) and five (4.9 %) suffered from other complications. At discharge, 27 (21.3 %) patients had 
favorable outcome (mRS 0 to 1), 57 patients (44.9 %) were dependent or worse (mRS 3 to 6), 
out of which eight patients (6.3 %) died before leaving hospital (Table V). Complications to 
anticoagulation treatment in hospital are described in Table VI. Other treatments were 
decompressive craniectomy (n=9, 7.1 %), hematoma evacuation (n=6, 4.7 %), other surgery 
(n=14, 11.1 %) and anticonvulsive drugs including direct seizure preventing drugs as 
diazepam (n=39, 31 %). 
 
 
 
 
 
Table V. Outcome at discharge (n=127) 
Modified Rankin Scale No. of cases % 
0 6 4.7 
1 21 16.5 
2 43 33.9 
3 23 18.1 
4 8 6.3 
5 18 14.2 
Death 8 6.3 
Good early outcome (0-1) 27 21.3 
Death or dependency (3-6) 57 44.9 
NIHSS (1 missing)   
0-2 96 76.2 
>2 18 14.3 
Intubated or postictal state 4 3.1 
Deceased 8 6.3 
Glasgow Coma Scale   
3 8 6.3 
4-8 4 3.1 
9-14 2 1.6 
15 113 89 
NIHSS – National Institutes of Health Stroke Scale 
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Table VI. Complications in hospital and different types of anticoagulation treatment among 
patients with cerebral venous thrombosis. 
 
 
Part 2 – Long-Term Outcome 
Out of 127 patients at baseline, 25 (19.7 %) were deceased at the time of long-term follow-up 
whereof eight patients (6.3 %) died in the acute phase. After exclusion of 37 patients 
(deceased n=25, living abroad n=4, onset age >63 years n=8), 90 patients were invited to the 
second part of the study including long-term follow-up. Ten patients declined participation, 
28 could not be reached, ten did not decide whether they wanted to participate or not, one was 
excluded due to uncertain diagnosis and two because of severe underlying psychiatric illness. 
Altogether 39 patients participated in the long-term follow-up study, (clinical visit n=34, 
telephone n=5). Median length between diagnosis and follow up was 134 months (IQR 61 to 
187). Four patients (10.5 %) had a recurrent thrombotic disease out of which two patients (5.3 
%) had a recurrent CVT. Long-term outcome and residual symptoms are summarized in Table 
VII and VIII. According to the mRS about half of the patients (53.8 %) had no or mild 
symptoms and were able to resume pre-stroke activities (mRS 0 to 1). According to the BI all 
but three patients were independent in activities of daily living (94.7 %). The most self-
reported complaints (Appendix I) at follow-up were memory or concentration disorder (n=24, 
61.5 %), headache (n=15, 38.5 %), psychiatric problems (n=12,  
 Complication in Hospital Number of cases % 
Treatment - Intravenous or Subcutaneous 
Anticoagulation 
Yes 
No 95 80.5 
Bleeding 11 9.3 
Other 12 10.2 
No 
No 6 75.0 
Bleeding 1 12.5 
Other 1 12.5 
Treatment - Local Thrombolysis 
Yes 
No 10 41.7 
Bleeding 6 25.0 
Other 8 33.3 
No 
No 92 89.3 
Bleeding 6 5.8 
Other 5 4.9 
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Table VIII. Residual symptoms, and functional outcome at long-term follow-up among patients 
surviving cerebral venous thrombosis (n=39). 
31.6 %) and fatigue (n=11, 28.9 %). Seven 
patients (18.4 %) were free from symptoms at 
follow-up. Most patients had no or only mild 
neurological deficits (NIHSS score 0-2, n=31, 
91.2 %). In Chi2 tests, occurrence of fatigue, 
headaches, dizziness, speech disorder, motoric 
problems or psychiatric problems at follow-up, 
were all individually significantly associated 
with not having returned to work (p<0.044 for 
all).  
 
Vocational Outcome 
Twenty-eight patients (71.8 %) were able to return to work within the follow-up period. 
Eleven patients (28.2 %) were still on sick leave or disability pension, all as a consequence of 
the residual symptoms from their CVT. Kaplan Meier plot is presented in Figure VI. The 
Table VII. Clinical outcome at long-term follow-
up among patients surviving cerebral venous 
thrombosis (n=39). 
Modified Rankin Scale No. of cases % 
0 8 21.1 
1 13 34.2 
2 11 28.9 
3 5 12.8 
4 1 2.6 
5 0 0 
Fully recovered (0-1) 21 55.3 
Dependent (3-5) 6 15.4 
NIHSS (5 missing)   
0-2 31 91.2 
>2 3 8.8 
 No. of 
cases 
% Missing 
data 
 No. of 
cases 
% Missing 
data 
Residual symptoms        
Epilepsy 4 10.3  Recurrent 4 10.5 1 
Spasticity 0 0  Thrombosis    
Tremor 1 2.6 1    CVT 2 5.3 1 
Headache 15 38.5     DVT 1 2.6 1 
Memory or 
concentration disorder 
24 61.5     LE 1 
 
2.6 
 
1 
 
Dizziness 5 13.2 1 Barthel Index <100 3 5.3 1 
Visual problem 6 15.8 1     
Linguistic disorder 9 23.7 1 Work return 28 71.8  
Pain 1 2.6 1 No work return 11 28.2  
Motor disorder 5 13.2      
Fatigue 11 28.9  Cryptogenic CVT 12 31.6 1 
Psychiatric problems 12 31.6 1     
Other symptom 7 18.4 1     
No symptoms 7 18.4 1     
NIHSS – National Institutes of Health Stroke Scale 
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cumulative proportion of patients who had returned to work at one, two, and three years 
where 48.7 %, 61.5 % and 71.8 %, respectively. Results from bivariate cox regression 
analyses are shown in Table IX. Time to work return was set as dependent factor. After 
adjusting for age and sex, absence of acute infarction, absence of acute intracranial event 
(subarachnoid hemorrhage, parenchymal hemorrhagic or non-hemorrhagic lesion, acute 
infarction), straight sinus thrombosis, estrogen use among women, and male sex were 
significantly associated with favorable outcome (p<0.05). Hematological condition, detected 
papilledema, multiple involvement of sinuses, mRS >2 upon discharge had p-values <0.1, but 
were not found significant after adjusting for age and sex. Based upon clinical- and theoretical 
experience, onset age >39, >2 risk factors, previous thrombosis and parenchymal or 
subarachnoid hemorrhage were put into a multivariable cox regression analysis, but no 
significance was found. The cohort was too small to perform further trustworthy multivariable 
analyses. 
 Table IX. Predictors of work return after cerebral venous thrombosis. 
 Work return  No work return  
(n=28)                   (n=11) 
 Adjusted for age and sex 
HR 95 % CI P HR 95 % CI P 
Gender, male 12 (42.9) 3 (27.3) 1.859 0.86-4.04 0.117 3.279 1.31-8.23 0.011 
Straight sinus 
thrombosis 
7 (25) 0 (0) 2.430 1.01-5.87 0.049 3.462 1.35-8.98 0.010 
Oral 
contraceptives* 
8 (28.6) 2 (20) 3.027 1.11-8.29 0.031 3.341 1.06-10.65 0.040 
Absence of acute 
infarction 
23 (82.1) 4 (36.4) 3.004 1.13-8.00 0.028 3.744 1.38-10.15 0.009 
Absence of acute 
intracranial event 
13 (46.4) 2 (18.2) 2.867 1.33-6.19 0.007 2.487 1.14-5.41 0.022 
Age <39 13 (46.4) 3 (27.3) 1.633 0.76-3.49 0.206 2.172 0.95-4.94 0.065 
>1 sinus involved 27 (96.4) 6 (54.5) 8.404 1.14-62.14 0.037 7.616 0.98-58.99 0.052 
Hematological 
condition  
(anemia, PV, ET) 
1 (3.6) 0 (0) 6.923 0.8-59.3 0.077 3.826 0.43-34.26 0.230 
Papilledema 5 (17.9) 0 (0) 2.979 1.06-8.35 0.038 1.875 0.58-6.07 0.294 
mRS discharge >2 10 (35.7) 5 (45.5) 0.457 0.20-1.03 0.058 0.468 0.21-1.06 0.069 
*Among women 
PV=Polycythemia Vera, ET=Essential Thrombocythemia, mRS=modified Rankin Scale 
Numbers are presented as n (%) 
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Discussion  
Description of Study and Main Findings 
This single-center retrospective study including 127 consecutive CVT patients provides 
comprehensive data on clinical presentation, risk factors, radiological findings, and long-term 
functional outcomes. Our primary aim was to investigate long-term vocational outcome. 
Thirty-nine patients were evaluated at long-term follow-up. A vast majority of patients were 
functionally independent, scoring 0 to 2 on the mRS (n=32, 84.2 %). However, all but 18.4 % 
reported residual symptoms from CVT, and over one quarter (28.2 %) of the surviving 
patients were not able to return to work, following complications from their CVT.  - Our 
Work Return 
Figure VI. Kaplan Meier plot on time to work return after diagnosis of cerebral venous thrombosis. 
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study suggests consequences of residual symptoms to negatively affect ability to return to 
work.  
Demographics 
The whole study population (n=127) differs from earlier studies with a somewhat older 
median age; 45 vs 37-39 years (8, 12). This may explain the relatively lower proportion of 
females (64.6 %, vs 74.5 % in ISCVT), who tend to be younger at onset as a result of gender-
specific risk factors (8).  
Clinical Presentation 
Notably, almost all presenting symptoms were less frequent than in the ISCVT, despite the 
belief of elder patients being more severely affected, probably as a cause of the retrospective 
design (8). Nevertheless, the interrelationship between symptoms were very much alike 
previous studies. Contrary to the trend, 27.8 % presented with any seizure in comparison with 
39.3 % in the ISCVT. Dichotomized to generalized seizures, the differentiation was less 
severe; 25.4% vs 30%, matching relatively less frequent parenchymal lesions on admission 
52.8 % vs 62.9 % in the ISCVT and brain infarctions 40.9 % vs 46.5 % (8). 
 
Inconsequent to more favorable presenting symptoms, our study population scored higher on 
the mRS at discharge compared to previous studies. Due to the retrospective design, a relative 
overestimation bias is possible. On the other hand, follow-up score assessed at clinical visit or 
by telephone, differed likewise. All assessments of mRS and NIHSS were performed by 
clinicians certified by a net-course from the University of Glasgow.  
Risk Factors and Etiology 
Found risk factors and etiology were very much in accordance with previous studies (8, 19, 
51). Though, genetic thrombophilia was only found in 16.5 % of the cases, compared to 22.4 
% in the ISCVT study (8). Although positive laboratorial findings ought to be documented in 
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medical records, some cases lacked data in the laboratorial module. Extensive laboratorial 
records were requested for, but not received at the end of the study. Again, retrospective 
designs have limitations compared to the ISCVT, where extensive laboratory investigations 
were encouraged. However, causes of thrombophilia were tested as a routine procedure 
throughout the study period. Interestingly, no patient had any known family history of CVT, 
but reliable data is lacking in most retrospective cases. 
 
Gender-specific risk factors were frequently present in females, 51.9 % under age of 50 used 
oral contraceptive drugs comparable to 52 % in the ISCVT and 52.2 % in the Lille study (8, 
51). Previous studies showed more favorable outcome in women with gender-specific risk 
factors, compared to other women and men (16).  
 
Malignancy or intracranial tumor was found in 11 % of the patients (7.9 % malignancies). In 
the ISCVT 7.4 % cases were associated with cancer (8). Hence, the search for malignancy and 
tumors seems to be of utmost importance in CVT patients. An unpublished multicenter study, 
currently in progress in the Netherlands, will provide more statistical power on this matter by 
a larger number of patients, including the Gothenburg patient group (27). Etiology was not 
confirmed in as much as 31.6 % of the follow-up group, a substantial difference to the ISCVT 
cohort where only 12.5 % were cryptogenic (8).  
Treatment, Complications, Radiological Findings 
This study allowed inclusion of patients transferred to Sahlgrenska University Hospital, 
Gothenburg from other hospitals. Patients in need of neurointerventional techniques, usually 
in inferior condition, might have caused referral bias. In six patients (4.7 %) a dural 
arteriovenous fistula (DAF) was found. In the ISCVT population, merely 1.6 % presented 
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with fistulas (8). The relationship between CVT and DAF remains unknown. Future studies 
are needed to investigate what causes the other. 
 
Local thrombolysis was performed to a greater extent (18.9 %) than in previous reports on 
other populations (ISCVT – 2.1 %). The matter is controversial, and there is a potential 
publication bias with under-reporting of cases with poor outcome and complications (7, 9). A 
randomized trial to evaluate local thrombolysis is currently ongoing (58). As presented in 
Table VI, patients receiving local thrombolysis were more likely to suffer from bleeding 
complications, 25 % vs 5.8 %. However, treated patients were probably already in severe 
clinical condition and at higher risk of fatal or irreversible consequences of the CVT. In the 
baseline group, almost all patients received treatment with subcutaneous or intravenous 
anticoagulation (n=118, 93.7 %). Bleeding occurred as a complication in 11 of these patients; 
however, 6 of them received simultaneous treatment with local thrombolysis.  
Mortality in Hospital 
Eight patients (6.3 %) died in the acute phase before leaving the hospital, slightly higher than 
in the ISCVT (4.3 %). At six months, no additional death had occurred, supporting previous 
rather low short-term mortality rates <10 % (14). Upon long-term follow-up, altogether 25 
patients were deceased, but causes of death were not analyzed in this study. Previous studies 
have shown that patients surviving the acute phase are likely to die from underlying diseases 
rather than from complications to their CVT (47). 
Long-Term Outcome 
In a recently published international retrospective multicenter study (n=706), recurrence of 
CVT and VTE was 4.4 % and 6.5 % respectively (59), in accordance to our study, where 10.5 
% had any recurrence of venous thrombosis and 5.3 % recurrence of CVT. In our study, few 
patients were spared from residual symptoms upon follow-up (18.4 %). Nevertheless, only 
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three patients scored <100 on the BI. Consistent with previous studies, occurrence of 
psychiatric problems (31.6 %), fatigue (28.9 %) and headache (38.5 %) were frequent (8, 53, 
54). It must be noted that most residual symptoms were self-reported, although being 
evaluated and confirmed upon follow-up. 
Vocational Outcome 
All vocational analyses were performed based on self-reported employment data at risk for 
recall bias. However, at follow-up the self-reported employment data were discussed and 
evaluated. Additionally, patients were encouraged to validate specific dates of work return 
against any insurance document kept in their possession. According to the Kaplan Meier plot 
(Fig. VI), a shift where few patients return to work independent on further elapsed time occur 
approximately 800 days after diagnosis, indicating for CVT patients as group, most crucial 
recovery associated with work return have been achieved after 2 years. Working ability after 
CVT has only been investigated in small studies, largest so far conducted by Hiltunen et. al. 
ninety-one patients (75.2 % of 121 patients included in the vocational analysis) were 
employed at follow-up (53). In our study, 28 patients (71.8 %) were able to return to work 
within the follow-up period, and 11 (28.2 %) never regained their working ability. Even 
though having good outcome according to the mRS, more than a quarter were not able to 
return to work, suggestive of the mRS to be a rather imprecise tool when measuring long-term 
functional outcome in young adults. Non-medical aspects as national public economy, general 
employment rate, and sick retirement benefits and rules also affect employment rates. In 
comparison, sick leave rate overall in Sweden, last quarter of 2015, was 3.1 % (60). 
Unemployment in the Swedish population in general was 7.5 % (n=376700, 2015, ages 16-64, 
7.7 % men n=201700, 7.3 % women n=175000). The more accurate number of unemployed 
according to the definition of this study would be even lower, due to the inclusion of full-time 
students in the unemployed group (women n=59 700, men n=61 700) (61).  
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Our study support previous reports on oral contraceptive use to be associated with more 
favorable outcome after CVT compared to other females (16, 53). Hiltunen et al. specifically 
reported a significant association between use of oral contraceptives at onset and being 
employed at long-term follow-up (OR 0.31, CI 0.10 to 0.95, p=0.040) (53). Further studies 
are needed to evaluate the mechanism.  
 
Female sex has previously been reported associated with more favorable outcome compared 
to males (16). Contradictory, our analyses implies the male sex to have a better chance for 
returning to work, although the confidence interval is wide-ranging (HR=3.279, CI 1.31 to 
8.23, p=0.011). Social gender aspects with different expectations on work return, both from 
the society and individually, may partly explain this difference. 
 
Theoretically, straight sinus thrombosis is considered involved in more severe cases of CVT 
as a cause of a higher risk of diencephalon and mesencephalon damage. Contrary, our results 
suggest association with higher work return rate (HR 3.462, CI 1.35 to 8.98). Prior to the 
follow-up analyses, deceased cases were excluded and might have caused a selection bias. 
Therefore, the analysis was only taking survivors in concern. At baseline, straight sinus 
thrombosis was detected in 28 patients (22.2 %). Out of the eight patients deceased in the 
acute phase, six had straight sinus involvement. Merely seven of the remaining 22 were seen 
at long-term follow-up. Outcome following aggressive treatment could be either tremendously 
good, or tremendously bad. Additionally, extraordinary positive alteration in condition is 
possible to enhance the motivation to participate in a follow-up study, causing selection bias. 
 
No development of infarction during acute hospital stay was significantly associated with 
work return after adjustment for age and sex, though the 95 % confidence interval was widely 
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spread (HR=3.774, CI 1.38 to 10.15). In the Helsinki study and a recent French study, no such 
association was detected (53, 62). Nevertheless, infarction in the acute phase predicting 
negative prognosis is both biologically plausible and supported in the ISCVT (8). 
Enlargement of the study group is likely to narrow the confidence interval. 
 
Subgrouping of patients according to their clinical characteristics could be of benefit in 
clinical practice, due to the wide panorama of presentation and the rather heterogeneous CVT 
population. One subgrouping, easy to interpret and applicable in clinical practice is the 
occurrence of any intracranial event during the acute phase. Our study suggests absence of 
any intracranial event – parenchymal hemorrhagic/non-hemorrhagic lesion, infarction or 
subarachnoid hemorrhage, to have positive impact on work return (HR 2.487, 95 % CI 1.14 to 
5.41).  
Methodological Considerations 
With a baseline population of 127 patients, this study contributes with one of the large single 
center CVT cohorts internationally. To our knowledge, this is the first Swedish study on 
cerebral venous thrombosis. An important strength of this study is the homogenous patient 
cohort, recruited from a predefined area which contributes to decrease risk of ascertainment 
bias. 
 
The three most important limitations of the study are the partly retrospective design, the 
modest sample size, and the substantial loss of patients at follow-up. In cross sectional follow 
up studies, patients with events or active problems are more likely to respond. Also, self-
reported symptoms are at risk for reporting bias, cognitive symptoms in particular. In future 
studies, objective assessment of cognitive problems would be of interest. Prospective studies, 
inevitably contribute more reliable data, however, retrospective studies contribute descriptive 
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data of great importance for creation of hypotheses, certainly in rare diseases where large 
patient materials are hard to reach.  
 
All statistical results from part 2 of the study based on long-term follow-up data, must be 
evaluated taking the modest sample size into account. The uncertainty of results can be 
observed in the relatively wide ranged confidence intervals and the limited number of factors 
included in multivariable analyses. Enlargement of the patient cohort is likely to contribute to 
narrow the intervals, and increasing the statistical power. 
 
This study provides interesting results, yet confirmations from studies with larger patient 
material are needed. The participation rate of less than 50 % of eligible patients is 
unsatisfactory, yet present. Recruitment of patients to this particular study is ongoing. A 
larger multivariable analyses could provide more reliable data on predictors of 
unemployment. Due to the relative rarity of CVT, such patient numbers can only be reached 
through international collaborations. 
Conclusions 
Although most CVT patients recovered well and were functionally independent, about a 
quarter of the survivors (28.2 %) were not able to return to work in the long-term. Individual 
predictors for work return were absence of acute intracranial event, absence of acute 
infarction, oral contraceptive use among females, straight sinus thrombosis, and male sex.  
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Populärvetenskaplig Sammanfattning 
Cerebral ventrombos (CVT): en studie med fokus på långtidsprognos och återgång till 
arbete 
Erik Lindgren, 2016 
Handledare: Turgut Tatlisumak och Katarina Jood 
 
Cerebral ventrombos (sinustrombos) är ett relativt ovanligt tillstånd som innebär 
blodproppsbildning i hjärnans vensystem (blodkärl som för blodet tillbaka till hjärtat). I 
genomsnitt drabbas 8 personer per miljon invånare per år, främst unga i arbetsför ålder och 
företrädesvis kvinnor. De bakomliggande orsakerna är till viss del kända och utgörs av både 
ärftliga faktorer och miljöfaktorer, men för cirka en tredjedel av dem som drabbas kan man 
inte fastställa orsaken trots noggrann utredning. Vanliga riskfaktorer är p-piller, graviditet, 
vissa blodsjukdomar och cancer. Sinustrombos kan i akutskedet ge svår huvudvärk och även 
leda till hjärninfarkt och/eller hjärnblödning. Tillståndet kan få konsekvenser på längre sikt 
och det är inte ovanligt att drabbade rapporterar funktionsnedsättning som 
koncentrationssvårigheter, huvudvärk, uttröttbarhet, depression och epilepsi. Förhållandevis 
lite forskning har gjorts på sinustrombos med tanke på det stora värdet av god behandling och 
rehabilitering, inte bara för de unga individer som drabbas och deras anhöriga, utan även ur ett 
samhällsekonomiskt perspektiv. 
 
Syftet med denna studie var därför att undersöka förekomsten av dessa följdsymptom mer 
noggrant och studera hur dessa symptom hör ihop med om patienter med sinustrombos kunnat 
återgå till arbete eller ej efter sin sjukdom.  
 
Efter att ha granskat journaler från vuxna patienter som insjuknat eller behandlats för 
sinustrombos på Sahlgrenska Sjukhuset, Göteborg, mellan 1997 och 2015, kunde vi 
konstatera att de vanligaste symptomen vid insjuknande var huvudvärk, illamående och 
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kräkning. Tidigare forskning har presenterat liknande resultat. I studien undersöktes även 
patienter minst ett år efter sitt insjuknande för att studera kvarvarande symptom och om de 
kunnat återgå till arbete eller ej. Totalt deltog 39 patienter i denna uppföljning. Det visade sig 
att majoriteten mådde mycket bra rent fysiskt och var oberoende av hjälp för att klara av att 
utföra sina dagliga aktiviteter. Trots det, hade mer än en fjärdedel (28 %) av patienterna inte 
kunnat återgå till arbete efter sin sjukdom. Vissa faktorer och omständigheter var vanligare i 
gruppen som kunde gå tillbaka till arbete. Dessa faktorer var manligt kön, sinustrombos bland 
kvinnor som tagit p-piller, om man inte hade hjärninfarkt och om man inte hade förekomst av 
tecken på hjärnskador under röntgenundersökning.  
 
Vår studie bekräftar alltså att trots att sinustrombos är en ovanlig sjukdom, så är den kritisk 
för de patienter som drabbas. Att vara ofrivilligt utesluten från arbetslivet har en negativ 
påverkan på livskvalitet, visar tidigare forskning. Det är svårt att samla stora grupper patienter 
från samma område, och internationella samarbeten behövs för att kunna göra mer 
tillförlitliga statistiska beräkningar. Ytterligare studier med fler patienter behövs för att 
bekräfta våra resultat för att vi i framtiden ska kunna identifiera och ge förbättrat stöd och 
behandling till de personer som har ökad risk att utveckla följdsymptom som påverkar 
återgång till arbete efter sinustrombos. 
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